Remi Gaston-Dreyfus insider trades: Bionik Laboratories (BNKL) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Remi reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 9, 2023 | BNKL | ↑ Buy | 180,555 | $0.60 | $108K | Shares held through GD Holdings and Lomb | Jun 21, 2023 (12d) |
| Aug 26, 2019 | BNKL | ↑ Buy | 106,358 | $3.76 | $400K | Shares held through RGD Investissements | Aug 28, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Remi Gaston-Dreyfus's insider trades
Remi Gaston-Dreyfus is a director at Bionik Laboratories (BNKL). Since Aug 26, 2019, Remi has reported 2 open-market purchases worth $508K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include conversions (8 filings), grants and awards (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BNKL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.